Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9973-9981

  Philip, Subha ^a   Swaminathan, Srividya ^a,d   Kuznetsov, Sergey G ^a   Kanugula, Sreenivas ^c   Biswas, Kajal ^a   Chang, Suhwan ^a   Loktionova, Natalia A ^c   Haines, Diana C ^b   Kaldis, Philipp ^a   Pegg, Anthony E ^c   Sharan, Shyam K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; 6 O METHYLGUANINE; ALKYL GROUP; ALKYLATING AGENT; AMINO ACID; BRCA2 PROTEIN; CISPLATIN;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EMBRYO; FAMILIAL CANCER; FIBROBLAST; GENE DELETION; GENE MUTATION; GERM LINE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING;

ALKYLATING AGENTS; AMINO ACID SEQUENCE; ANIMALS; BRCA2 PROTEIN; DNA REPAIR; GENE DELETION; GUANINE; HUMANS; METHYLNITRONITROSOGUANIDINE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 57149097470     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1179     Document Type: Article

References (46)

1. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998;32:95-121.
2. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
3. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
4. Evers B, Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006;25:5885-97.
5. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
6. Suzuki A, de la Pompa JL, Hakem R, et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997;11:1242-52.
7. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997;11:1226-41.
8. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57.
9. McAllister KA, Bennett LM, Houle CD, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 2002;62:990-4.
10. Donoho G, Brenneman MA, Cui TX, et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA cross-links, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer 2003;36:317-31.
11. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997;17:423-30.
12. Friedman LS, Thistlethwaite FC, Patel KJ, et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res 1998;58:1338-43.
13. Atanassov BS, Barrett JC, Davis BJ. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2-2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair but does not affect meiosis. Genes Chromosomes Cancer 2005;44:429-37.
14. Ludwig T, Fisher P, Murty V, Efstratiadis A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 2001;20:3937-48.
15. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-4.
16. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998;95:5287-92.
17. Swaminathan S, Ellis HM, Waters LS, et al. Rapid engineering of bacterial artificial chromosomes using oligonucleotides. Genesis 2001;29:14-21.
18. Kanugula S, Pegg AE. Novel DNA repair alkyltransferase from Caenorhabditis elegans. Environ Mol Mutagen 2001;38:235-43.
19. 6-methylguanine-DNA methyltransferase. J Biol Chem 1982;257:13776-80.
20. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
21. 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 1996;35:1328-34.
22. 6-alkylguanine-DNA alkyltransferase. J Med Chem 1992;35:4486-91.
23. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990;87:5368-72.
24. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85.
25. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A 1999;96:13920-5.
26. Donawho CK, Luo Y, Penning TD, Bauch JL, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
27. Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005;65:10145-8.
28. De Soto JA, Wang X, Tominaga Y, et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006;2:179-85.
29. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
30. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
31. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.
32. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004;21:543-52.
33. 6-Alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002;24:255-66.
34. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
35. 6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006;6:355-63.
36. Dong J, Chang-Claude J, Wu Y, et al. A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3′ third of the gene. Hum Genet 1998;103:154-61.
37. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995;51:167-223.
38. 6-benzylguanine or N-methyl-N¶-nitro-N- nitrosoguanidine. Carcinogenesis 1991;12:1679-83.
39. Glassner BJ, Weeda G, Allan JM, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis 1999;14:339-47.
40. Tsuzuki T, Sakumi K, Shiraishi A, et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 1996;17:1215-20.
41. Sakumi K, Shiraishi A, Shimizu S, Tsuzuki T, Ishikawa T, Sekiguchi M. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res 1997;57:2415-8.
42. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
43. 6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 2006;32:261-76.
44. 6-benzylguanine. Cancer Chemother Pharmacol 2005;55:333-42.
45. Fishel ML, Newell DR, Griffin RJ, et al. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 2005;312:206-13.
46. 6-benzylguanine. Mol Cancer Ther 2003;2:633-40.